Descriptors and administrative fields exactly as published in the CMS HCPCS quarterly file.
Billing context: J-codes
Units are reported in multiples of the dosage in the code descriptor.
One HCPCS billing unit of J2469
25 MCG
Medicare payment limit per unit (Q4 2026): $0.469
| Setting | Max units / day | Adjudication (MAI) | CMS rationale |
|---|---|---|---|
| Practitioner services (professional claims) | 60 | 3 Date of Service Edit: ClinicalDate-of-service edit (clinical benchmarks): more units for the same patient and date are possible but medically highly unlikely; documentation of medical necessity may be considered. | Prescribing Information |
| Facility outpatient hospital services | 60 | 3 Date of Service Edit: ClinicalDate-of-service edit (clinical benchmarks): more units for the same patient and date are possible but medically highly unlikely; documentation of medical necessity may be considered. | Prescribing Information |
| DME supplier services | 0Not reportable in this setting | 3 Date of Service Edit: ClinicalDate-of-service edit (clinical benchmarks): more units for the same patient and date are possible but medically highly unlikely; documentation of medical necessity may be considered. |
Medicare Part B drug payment limits per billing unit, by quarter, from the CMS payment limit (ASP) files.
Current Medicare Part B payment limit · Q4 2026
$0.469per 25 MCG
Effective Oct 1, 2026 – Dec 31, 2026 · AMP-based payment limit (per CMS note) · based on Q2 2026 ASP data · coinsurance 20.000%
CMS note: “AMP-based payment limit”
| Quarter | Effective | Payment limit | Per (billing unit) | Coinsurance | Change | CMS notes |
|---|---|---|---|---|---|---|
| Q4 2026 | Oct 1, 2026 – Dec 31, 2026 | $0.469 | 25 MCG | 20% | −18.3% | AMP-based payment limit |
| Q3 2026 | Jul 1, 2026 – Sep 30, 2026 | $0.574 | 25 MCG | 20% | −11.6% |
Medicare hospital outpatient (OPPS) · Q4 2026
N Packaged: no separate payment
Washington Apple Health · professional claims
AAC = actual acquisition cost, based on NDC or invoice; BR = by report; NC = not covered; DC = not covered, see a different code; DP = covered under another program (see comments); PA = prior authorization; EPA = expedited prior authorization (see the billing guide); CPA = contractor prior authorization (Qualis). For professional claims; hospital-administered drugs are paid under HCA's outpatient (OPPS/EAPG) rules.
Packages CMS assigns to this code in its NDC–HCPCS crosswalks, with billable units per package. Only official crosswalk rows are shown.
| NDC (11-digit) | CMS drug name · labeler | Pkg size × qty | Units / item | Units / NDC | Derived $ / NDC | Crosswalk | Quarters | FDA listing |
|---|---|---|---|---|---|---|---|---|
| 60505-6193-01 | PalonosetronApotex Corp | 5 × 1 | 10 | 10 | $4.69 | ASP | Q1 2021 – Q4 2026 | ListedPalonosetron |
| 60505-6193-04 | Palonosetron HClApotex Corp | 5 × 10 | 10 | 100 | $46.90 | ASP | Q2 2026 – Q4 2026 | ListedPalonosetron |
| 60505-6439-01 | Palonosetron HydrochlorideApotex Corp | 5 × 1 | 10 | 10 | $4.69 | ASP | Q2 2026 – Q4 2026 | ListedPalonosetron |
| 83634-0777-05 | Palonosetron HClAvenacy Inc. | 5 × 1 | 10 | 10 | $4.69 | ASP | Q1 2025 – Q4 2026 | Excluded listingPalonosetron Hydrochloride |
| 36000-0326-02 | PalonosetronBaxter Healthcare Corporation | 5 × 1 | 10 | 10 | $4.69 | ASP | Q3 2022 – Q4 2026 | ListedPalonosetron Hydrochloride |
| 68001-0355-25 | PalonosetronBluePoint Laboratories | 5 × 1 | 10 | 10 | $4.69 | ASP | Q1 2021 – Q4 2026 | ListedPalonosetron |
| 55111-0694-07 | PalonosetronDr. Reddy's Laboratories Inc. | 5 × 1 | 10 | 10 | $4.69 | ASP | Q1 2021 – Q4 2026 | ListedPalonosetron |
| 55150-0186-05 | PalonosetronEugia US LLC | 5 × 1 | 10 | 10 | $4.69 | ASP | Q1 2021 – Q4 2026 | ListedPalonosetron Hydrochloride |
| 63323-0673-05 | PalonosetronFreseniUS Kabi USA, LLC | 5 × 1 | 10 | 10 | $4.69 | ASP | Q1 2021 – Q4 2026 | ListedPalonosetron |
| 63323-0673-89 | PalonosetronFreseniUS Kabi USA, LLC | 5 × 10 | 10 | 100 | $46.90 | ASP | Q1 2021 – Q4 2026 | ListedPalonosetron |
| 71288-0409-05 | PalonosetronMeitheal Pharmaceuticals Inc. | 5 × 1 | 10 | 10 | $4.69 | ASP | Q1 2024 – Q4 2026 | ListedPalonosetron Hydrochloride |
| 67457-0317-25 | PalonosetronMylan Institutional LLC | 5 × 1 | 10 | 10 | $4.69 | ASP | Q1 2021 – Q4 2026 | ListedPalonosetron Hydrochloride |
| 16714-0834-01 | PalonosetronNorthstar RxLLC | 5 × 1 | 10 | 10 | $4.69 | ASP | Q1 2021 – Q4 2026 | ListedPalonosetron |
| 00409-2504-10 | PalonosetronPfizer Inc | 5 × 1 | 10 | 10 | $4.69 | ASP | Q1 2021 – Q4 2026 | Excluded listingPalonosetron Hydrochloride |
| 25021-0783-05 | PalonosetronSagent Pharmaceuticals | 5 × 1 | 10 | 10 | $4.69 | ASP | Q1 2021 – Q4 2026 | ListedPalonosetron Hydrochloride |
| 25021-0788-74 | PalonosetronSagent Pharmaceuticals | 5 × 5 | 10 | 50 | $23.45 | ASP | Q1 2021 – Q4 2026 | Excluded listingPalonosetron Hydrochloride |
| 00781-3312-75 | PalonosetronSandoz Inc. | 5 × 1 | 10 | 10 | $4.69 | ASP | Q1 2021 – Q4 2026 | ListedPalonosetron Hydrochloride |
| 00781-3312-95 | PalonosetronSandoz Inc. | 5 × 10 | 10 | 100 | $46.90 | ASP | Q2 2025 – Q4 2026 | ListedPalonosetron Hydrochloride |
| 00781-3415-75 | PalonosetronSandoz Inc. | 5 × 1 | 10 | 10 | $4.69 | ASP | Q1 2021 – Q4 2026 | Excluded listingPalonosetron Hydrochloride |
| 00781-3415-95 | Palonosetron HClSandoz Inc. | 5 × 10 | 10 | 100 | $46.90 | ASP | Q3 2025 – Q4 2026 | Excluded listingPalonosetron Hydrochloride |
| 00703-4094-01 | PalonosetronTeva Parenteral Medicines, Inc. | 5 × 1 | 10 | 10 | $4.69 | ASP | Q1 2021 – Q4 2026 | ListedPalonosetron Hydrochloride |
| 69543-0371-10 | PalonosetronVirtus Pharmaceuticals, LLC | 5 × 10 | 10 | 100 | $46.90 | ASP | Q1 2021 – Q4 2026 | Excluded listingPalonosetron Hydrochloride |
Derived calculation “Derived $ / NDC” = billable units per NDC × the current payment limit. It is arithmetic for orientation, not a payment amount.
| NDC (11-digit) | CMS drug name · labeler | Pkg size × qty | Units / item | Units / NDC | Crosswalk | Quarters | FDA listing |
|---|---|---|---|---|---|---|---|
| 16729-0365-66 | PalonosetronACCORD HEALTHCARE INC. | 5 × 1 | 10 | 10 | ASP | Q1 2021 – Q4 2024Not in Q4 2026 file |
Medicare coverage is set nationally (NCDs) and by each Medicare Administrative Contractor (LCDs and Billing & Coding articles). These links open the official documents.
Verification neededCodeRx links to coverage documents instead of copying them: CMS distributes their code lists under AMA, ADA, and AHA license terms that limit reuse. Medicare Advantage, Medicaid, and commercial plans set their own coverage and prior-authorization rules.
Changes detected between the CMS quarterly HCPCS files CodeRx has imported.
| Quarterly file | Change | CMS action code | Details |
|---|---|---|---|
| Q1 2024 | Dates changed | P — Payment change | Added Jan 1, 2005 · action effective Jan 1, 2024 · termination — |
| Q1 2023 | In earliest ingested file | N — No maintenance | Added date Jan 1, 2005 |
All imported releases, checksums, and import reports are listed on the data sources page.
Disclaimer. This application provides informational coding and reimbursement reference data. It does not constitute legal, clinical, coding, or billing advice. Codes, payment amounts, payer rules, and coverage policies can change. Verify all information with current CMS publications, the applicable payer, and your organization’s compliance policies before submitting a claim. CodeRx is not affiliated with or endorsed by CMS, FDA, Medicare, or any payer.
| CMS Policy |
An MUE is the most units CMS expects for this code for one patient on one date of service by the same provider in most correctly reported claims. CMS MUE program
| AMP-based payment limit |
| Q2 2026 | Apr 1, 2026 – Jun 30, 2026 | $0.649 | 25 MCG | 20% | +83.9% | AMP-based payment limit |
|---|
| Q1 2026 | Jan 1, 2026 – Mar 31, 2026 | $0.353 | 25 MCG | 20% | −0.8% | AMP-based payment limit |
|---|
| Q4 2025 | Oct 1, 2025 – Dec 31, 2025 | $0.356 | 25 MCG | 20% | −20.0% | AMP-based payment limit |
|---|
| Q3 2025 | Jul 1, 2025 – Sep 30, 2025 | $0.445 | 25 MCG | 20% | −10.6% | AMP-based payment limit |
|---|
| Q2 2025 | Apr 1, 2025 – Jun 30, 2025 | $0.498 | 25 MCG | 20% | −15.6% | AMP-based payment limit |
|---|
| Q1 2025 | Jan 1, 2025 – Mar 31, 2025 | $0.590 | 25 MCG | 20% | −4.2% | AMP-based payment limit |
|---|
| Q4 2024 | Oct 1, 2024 – Dec 31, 2024 | $0.616 | 25 MCG | 20% | −36.9% | AMP-based payment limit |
|---|
| Q3 2024 | Jul 1, 2024 – Sep 30, 2024 | $0.977 | 25 MCG | 20% | −18.0% | — |
|---|
| Q2 2024 | Apr 1, 2024 – Jun 30, 2024 | $1.192 | 25 MCG | 20% | +41.1% | — |
|---|
| Q1 2024 | Jan 1, 2024 – Mar 31, 2024 | $0.845 | 25 MCG | 20% | −4.4% | — |
|---|
| Q4 2023 | Oct 1, 2023 – Dec 31, 2023 | $0.884 | 25 MCG | 20% | −11.7% | — |
|---|
| Q3 2023 | Jul 1, 2023 – Sep 30, 2023 | $1.001 | 25 MCG | 20% | −22.8% | — |
|---|
| Q2 2023 | Apr 1, 2023 – Jun 30, 2023 | $1.297 | 25 MCG | 20% | +28.0% | — |
|---|
| Q1 2023 | Jan 1, 2023 – Mar 31, 2023 | $1.013 | 25 MCG | — | −11.9% | — |
|---|
| Q4 2022 | Oct 1, 2022 – Dec 31, 2022 | $1.150 | 25 MCG | — | +27.1% | — |
|---|
| Q3 2022 | Jul 1, 2022 – Sep 30, 2022 | $0.905 | 25 MCG | — | −25.5% | — |
|---|
| Q2 2022 | Apr 1, 2022 – Jun 30, 2022 | $1.214 | 25 MCG | — | +41.7% | — |
|---|
| Q1 2022 | Jan 1, 2022 – Mar 31, 2022 | $0.857 | 25 MCG | — | −11.2% | — |
|---|
| Q4 2021 | Oct 1, 2021 – Dec 31, 2021 | $0.965 | 25 MCG | — | −49.2% | — |
|---|
| Q3 2021 | Jul 1, 2021 – Sep 30, 2021 | $1.900 | 25 MCG | — | −31.2% | — |
|---|
| Q2 2021 | Apr 1, 2021 – Jun 30, 2021 | $2.760 | 25 MCG | — | −13.3% | — |
|---|
| Q1 2021 | Jan 1, 2021 – Mar 31, 2021 | $3.185 | 25 MCG | — | — | — |
|---|
| 70860-0785-05 | PalonosetronAthenex Pharmaceutical Division, LLC | 5 × 1 | 10 | 10 | ASP | Q3 2023 – Q3 2026Not in Q4 2026 file | Excluded listingPalonosetron Hydrochloride |
|---|
| 69097-0439-35 | PalonosetronCIPLA USA INC. | 5 × 1 | 10 | 10 | ASP | Q1 2021 – Q4 2024Not in Q4 2026 file | Excluded listingPalonosetron Hydrochloride |
|---|
| 69097-0927-35 | PalonosetronCIPLA USA INC. | 5 × 1 | 10 | 10 | ASP | Q1 2021 – Q4 2024Not in Q4 2026 file | ListedPalonosetron Hydrochloride |
|---|
| 63323-0942-05 | PalonosetronFRESENIUS KABI | 5 × 10 | 10 | 100 | ASP | Q1 2021 – Q2 2022Not in Q4 2026 file | Excluded listingPalonosetron |
|---|
| 63323-0942-41 | PalonosetronFRESENIUS KABI | 5 × 1 | 10 | 10 | ASP | Q3 2021 – Q2 2022Not in Q4 2026 file | Not found |
|---|
| 62856-0797-01 | AloxiHELSINN THERAPUTICS (US) INC | 5 × 1 | 10 | 10 | ASP | Q1 2021 – Q3 2022Not in Q4 2026 file | Excluded listingAloxi |
|---|
| 69639-0103-01 | AloxiHELSINN THERAPUTICS (US) INC | 5 × 1 | 10 | 10 | ASP | Q1 2021 – Q4 2024Not in Q4 2026 file | Excluded listingAloxi |
|---|
| 00143-9513-01 | PalonosetronHikma Pharmaceuticals USA Inc. | 2 × 1 | 10 | 10 | ASP | Q1 2021 – Q4 2025Not in Q4 2026 file | Excluded listingPalonosetron Hydrochloride |
|---|
| 50742-0485-05 | PalonosetronINGENUS PHARMACEUTICALS, LLC | 5 × 1 | 10 | 10 | ASP | Q2 2021 – Q4 2024Not in Q4 2026 file | Excluded listingPalonosetron Hydrochloride |
|---|
| 69543-0371-01 | PALONOSETRON HCL INJECTION SINGLE VIALVIRTUS PHARMACEUTICAL | 5 × 1 | 10 | 10 | ASP | Q2 2022 – Q4 2023Not in Q4 2026 file | Not found |
|---|